Subtopic Deep Dive

Mastocytosis Pathogenesis
Research Guide

What is Mastocytosis Pathogenesis?

Mastocytosis pathogenesis involves clonal mast cell proliferation driven primarily by activating KIT mutations, particularly D816V in the tyrosine kinase domain, leading to systemic mast cell disorders.

Activating mutations in the c-KIT protooncogene, first identified by Nagata et al. (1995) with 877 citations, cause ligand-independent KIT signaling and mast cell accumulation. Longley et al. (1996, 607 citations) established clonality via somatic c-KIT mutations in urticaria pigmentosa and aggressive mastocytosis. Valent et al. (2016, 657 citations) updated WHO classification, emphasizing KIT D816V prevalence in advanced forms.

Curated Papers

Key Challenges

Why It Matters

KIT D816V mutations enable risk stratification for indolent versus aggressive systemic mastocytosis, guiding tyrosine kinase inhibitor therapies like midostaurin (Valent et al., 2016). Genetic analysis of bone marrow lineages informs prognosis, as shown in García-Montero et al. (2006, 491 citations) across 113 patients. Metcalfe (2008, 525 citations) links pathogenesis to clinical management, improving survival in hematologic-associated cases (Nagata et al., 1995).

Key Research Challenges

Heterogeneity of KIT Mutations

Distinct clinical forms show activating versus inactivating KIT mutations in the catalytic domain (Longley et al., 1999, 553 citations). Pediatric cases often regress, while adult forms progress due to variable mutation penetrance. Frequency varies across bone marrow lineages (García-Montero et al., 2006).

Clonality Establishment

Somatic c-KIT mutations confirm mast cell neoplasm clonality but require multi-lineage analysis (Longley et al., 1996). Peripheral blood mononuclear cells show mutations in associated hematologic disorders (Nagata et al., 1995). Prospective studies needed for systemic validation.

Therapy Resistance Mechanisms

KIT D816V confers resistance to certain tyrosine kinase inhibitors despite WHO updates (Valent et al., 2016). Metcalfe (2008) notes incomplete understanding of downstream signaling in mastocytosis evolution. Novel targets beyond KIT remain undefined.

Essential Papers

Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder.

H Nagata, A S Worobec, Chang Kyu Oh et al. · 1995 · Proceedings of the National Academy of Sciences · 877 citations

Both stem cells and mast cells express c-kit and proliferate after exposure to c-kit ligand. Mutations in c-kit may enhance or interfere with the ability of c-kit receptor to initiate the intracell...

Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts

Peter Valent, Cem Akin, Dean D. Metcalfe · 2016 · Blood · 657 citations

Abstract Over the past few years, substantial advances have been made in understanding the pathogenesis, evolution, and complexity of mast cell neoplasms. New diagnostic and prognostic parameters a...

Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm

B. Jack Longley, Lynda Tyrrell, Shu-Zhuang Lu et al. · 1996 · Nature Genetics · 607 citations

Activating and dominant inactivating c-<i>KIT</i>catalytic domain mutations in distinct clinical forms of human mastocytosis

B. Jack Longley, Dean D. Metcalfe, Michael D. Tharp et al. · 1999 · Proceedings of the National Academy of Sciences · 553 citations

Human mastocytosis is characterized by increased mast cells. It usually occurs as a sporadic disease that is often transient and limited in children and persistent or progressive in adults. The c- ...

Mast cells and mastocytosis

Dean D. Metcalfe · 2008 · Blood · 525 citations

Abstract Mast cells have been recognized for well over 100 years. With time, human mast cells have been documented to originate from CD34+ cells, and have been implicated in host responses in both ...

KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients

Andrés C. García‐Montero · 2006 · Blood · 491 citations

Despite the relevance of the c-kit/stem cell factor (SCF) signaling pathway in mast cell (MC) diseases, the exact frequency of KIT mutations in different compartments of bone marrow (BM) hematopoie...

An Inflammation-Centric View of Neurological Disease: Beyond the Neuron

Stephen D. Skaper, Laura Facci, Morena Zusso et al. · 2018 · Frontiers in Cellular Neuroscience · 431 citations

Inflammation is a complex biological response fundamental to how the body deals with injury and infection to eliminate the initial cause of cell injury and effect repair. Unlike a normally benefici...

Reading Guide

Foundational Papers

Start with Nagata et al. (1995, 877 citations) for initial c-KIT mutation discovery in mastocytosis with hematologic disorders; follow Longley et al. (1996, 607 citations) for clonality proof and Longley et al. (1999, 553 citations) for mutation-clinical correlations.

Recent Advances

Valent et al. (2016, 657 citations) for WHO updates and treatment concepts; Metcalfe (2008, 525 citations) for mastocytosis overview linking to histamine roles.

Core Methods

c-KIT sequencing in bone marrow (García-Montero et al., 2006); tyrosine kinase signaling assays; WHO classification criteria integrating genetics and histopathology (Valent et al., 2016).

How PapersFlow Helps You Research Mastocytosis Pathogenesis

Discover & Search

Research Agent uses searchPapers and citationGraph to map KIT mutation literature from Nagata et al. (1995, 877 citations), revealing 600+ connected papers on D816V prevalence. exaSearch queries 'KIT D816V mastocytosis bone marrow' for REMA network studies like García-Montero et al. (2006); findSimilarPapers expands to Longley et al. (1996) clonality works.

Analyze & Verify

Analysis Agent applies readPaperContent to extract mutation frequencies from Valent et al. (2016), then verifyResponse with CoVe chain-of-verification flags inconsistencies across Longley papers. runPythonAnalysis processes citation networks with pandas for mutation co-occurrence stats; GRADE grading scores evidence strength for D816V prognostic claims (e.g., high from Nagata et al., 1995).

Synthesize & Write

Synthesis Agent detects gaps in KIT inhibitor resistance via contradiction flagging between Metcalfe (2008) and Valent et al. (2016), generating exportMermaid diagrams of pathogenesis pathways. Writing Agent uses latexEditText and latexSyncCitations to draft reviews citing 20+ papers, with latexCompile producing camera-ready manuscripts on mastocytosis genetics.

Use Cases

"Extract KIT mutation frequencies from REMA study and plot vs. disease subtype."

Research Agent → searchPapers('García-Montero KIT mutation REMA') → Analysis Agent → readPaperContent → runPythonAnalysis(pandas barplot of 113-patient data) → matplotlib figure of mutation prevalence by lineage.

"Draft LaTeX review on KIT D816V evolution from Nagata to Valent."

Research Agent → citationGraph(Nagata 1995 to Valent 2016) → Synthesis Agent → gap detection → Writing Agent → latexEditText(structured sections) → latexSyncCitations(15 papers) → latexCompile(PDF with figures).

"Find GitHub repos analyzing mastocytosis single-cell RNA-seq datasets."

Research Agent → searchPapers('mastocytosis scRNA-seq KIT') → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect(analysis scripts for mutation expression) → runPythonAnalysis(replicate in sandbox).

Automated Workflows

Deep Research workflow conducts systematic review of 50+ KIT papers: searchPapers → citationGraph → DeepScan(7-step verify with CoVe) → GRADE report on pathogenesis evidence. Theorizer generates hypotheses on post-KIT signaling from Longley/Metcalfe synthesis. DeepScan analyzes mutation heterogeneity with runPythonAnalysis checkpoints on García-Montero dataset.

Try Doxa for Mastocytosis Pathogenesis Research

Frequently Asked Questions

What defines mastocytosis pathogenesis?

Clonal expansion of mast cells due to activating KIT mutations like D816V in the tyrosine kinase domain (Nagata et al., 1995; Longley et al., 1996).

What are key methods for studying KIT mutations?

Sequencing peripheral blood mononuclear cells and bone marrow lineages; clonality via somatic mutation detection (García-Montero et al., 2006; Longley et al., 1999).

What are seminal papers?

Nagata et al. (1995, 877 citations) identified c-KIT point mutation; Longley et al. (1996, 607 citations) proved clonality; Valent et al. (2016, 657 citations) updated WHO classification.